NASDAQ: SPRCScisparc Ltd Stock
$0.52-0.01 (-1.89%)
Updated Mar 24, 2023
SPRC Price
$0.52
Fair Value Price
$0.52
Market Cap
$1.61M
52 Week Low
$0.50
52 Week High
$5.00
P/E
-0.59x
P/B
1.87x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$2.56M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
3.75
Operating Cash Flow
-$1M
Beta
0.43
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SPRC Overview
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SPRC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPRC ($0.52) is overvalued by 0% relative to our estimate of its Fair Value price of $0.52 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SPRC ($0.52) is not significantly undervalued (0%) relative to our estimate of its Fair Value price of $0.52 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SPRC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SPRC due diligence checks available for Premium users.
Be the first to know about important SPRC news, forecast changes, insider trades & much more!
SPRC News
Valuation
SPRC fair value
Fair Value of SPRC stock based on Discounted Cash Flow (DCF)
Price
$0.52
Fair Value
$0.52
Overvalued by
0.00%
SPRC ($0.52) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SPRC ($0.52) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SPRC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SPRC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.59x
Industry
17.88x
Market
21.37x
SPRC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.87x
Industry
4.89x
SPRC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SPRC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
SPRC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.2M
Liabilities
$3.3M
Debt to equity
3.75
SPRC's short-term assets ($3.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPRC's short-term assets ($3.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPRC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SPRC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
SPRC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SPRC vs Biotech Stocks
Scisparc Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.